Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18844096 | 0.81 | ALDH1A1 (0.40) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL13704093 | 0.81 | KDM5A (0.41) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL6783917 | 0.81 | RAPGEF4 (0.46) | RAB9ANPC1MAPTKMT2AALDH1A1 | |
| SCHEMBL2324287 | 0.81 | KMT2A (0.46) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL90481 | 0.81 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL19444177 | 0.81 | SMN1; SMN2 (0.48) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL19791118 | 0.81 | ALDH1A1 (0.40) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL19632330 | 0.81 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL7125183 | 0.81 | ALDH1A1 (0.40) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL2658362 | 0.81 | ALDH1A1 (0.40) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053983-A1 | 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase | BARVIAN NICOLE CHANTEL (US) | 2004-03-18 | — | — | US | claimed |
| EP-1294687-A2 | 1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001096298-A2 | 1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-3466946-B1 | THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME | DONGBAO PURPLE STAR HANGZHOU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1294687-A2 | 1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001096298-A2 | 1,2,4-TRISUBSTITUTED BENZENES AS INHIBITORS OF 15-LIPOXYGENASE | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053983-A1 | 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase | ALOX15, ALOX5, ALOX15B | RAB9A 3743/4885NPC1 3031/4885SMN1; SMN2 4429/4885 |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | RAB9A 1308/4885NPC1 176/4885SMN1; SMN2 841/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | RAB9A 2872/4885NPC1 3790/4885SMN1; SMN2 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.